川芎嗪、参麦注射液对肺心病急性期血液流变性及临床疗效的影响

Clinical Influence and Hemorrheology of Ligustrazine and Shenmai Injection on Patients of Chronic Cor Pulmonale during Acute Attack

目的探讨川芎嗪、参麦注射液对肺心病急性期血液流变性、抗凝功能、纤溶功能的作用。方法将80例慢性肺心病急性期患者随机分为两组,均予以抗炎、止咳化痰、强心利尿及持续低流量吸氧等常规治疗,治疗组在此基础上加用川芎嗪注射液、参麦注射液静滴,共治疗2个疗程;观察两组临床疗效及对血液流变性、抗纤溶功能的改善作用。结果治疗组临床总有效率为88.0%,明显高于对照组之63.4%;其治疗后高切变率下全血黏度、低切变率下全血黏度、血浆黏度、红细胞聚集指数、红细胞电泳时间及纠维蛋白原与治疗前比较均显著下降,组间差异有显著性;治疗组血中抗凝血酶Ⅲ活性、纤溶酶原活性、组织型纤溶酶原激活物活性和纤溶酶原激活物抑制物活性均较对照组明显升高,改善肺心病患者的抗凝及纤溶功能明显优于对照组。结论川芎嗪、参麦注射液是治疗慢性肺心病急性期血液高凝状态的有效药物。

Objective： To investigate the clincal effect of Ligustravine and shenmai injection （SMI） on hemorrheology fibrinlytic system in treating patients of chronic cor pulomonale during acute attack. Method： 80 patients were divided into two group. 50 in the study group, 30 in the control group. Both groups were treated with conventional therapy including anti - inflammatatory, reliveing cough and reducing sputum, Cardial, diuretic and continoas Low - flow oxygen inhalation. For the study group, additional two courses of Ligustrazine and SMI were given intravenously for 7 days as one course with an interval of 6 days between course. The clinical therapeutic effect in the two groups and effect of treatment on hemrrheology and fibrinolytic fanction were observed. Results： The total effective rate in the study group was 88.0%, and that in the control group was 63.4%, the difference between the group was significant. After treatment in the study group, the high and low - shear whole blood Viscosity; Plasma Viscosity, erythocyte agglutination index, hematocrit and fibrinogen lowered obviously, as compared with before treatment. And the study group showed more potent effect in improving anti - coagulation and fibrinolytic function of patients than that of Ghe control group. Conclusions： Ligustrazine and SMI are effective drugs for treatment of hypercoagulability status in acute stage of chronic cor Pulmonale, and is worthy of clinical application.